Mallinckrodt Plc (MNKKQ) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access MNKKQ Annual Income Statement →
This income statement overview for Mallinckrodt Plc spans from Apr 01 2022 to Jun 30 2026, showing how the company's revenues, expenses, and earnings have changed across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
Q2 2026
(Jun 27 2025) (Dec 27 2024) (Jun 16 2022) (Apr 01 2022)
Revenues
Revenue From Contract With Customer Including Assessed Tax517.20
Total Revenue517.20
Costs & Expenses
Cost of Goods and Services Sold235.20
Gross Profit282.00
Selling, Administration, Marketing243.80
Depreciation & Amortization59.80
Research and Development Expense25.00
Restructuring Charges216.30
Other Operating Expense / -Income-59.80
Total operating costs including COS720.30
Operating income / -loss-203.10
Interest Expense0.00
Interest Income6.70
Net Interest (-)Expense / Income0.00
Extinguishment of Debt0.00
Loss / -Gain on Investment0.00
Other loss / -income0.00
Total costs & expenses760.70
Income & Taxes
Income / -loss before income taxes-243.50
Income taxes expenses / -benefit-23.00
Income after income taxes-220.50
Income / -loss from continuing operations-220.50
Discontinued operations0.00
Net income / -loss-220.50
Income / -loss to shareholder-220.50
EBIT-243.50
EBITD-147.60
EBITDA-57.80
Earnings Per Share
Basic EPS (excl. extra items)-5.57
Extraordinary items0.00
Basic Net EPS-5.57
Basic shares outstanding (Mill. of Units)39.60
Diluted Net EPS-5.57
Diluted average shares (Mill. of Units)39.60
4 historic quarters locked

Sign in to unlock the full Mallinckrodt Plc income statement history.

About Keenova Therapeutics Plc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: August 11, 2026
  • Original filing: mnk-20260630.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.